Direct accesses

  • Go to main menu
  • Go to main content
Menu
GenSight GenSight
Search the site
  • Contact
  • Careers
  • You are viewing the website in English en
  • fr
Search the site
  • Whowe are
    • Company
    • Leadership
    • Collaborations
  • Diseaseswe target
    • Diseases we target
    • Leber Hereditary Optic Neuropathy (LHON)
    • Retinitis Pigmentosa (RP)
    • Geographic Atrophy in Dry-AMD
  • Ourtechnologies
    • Technologies we are applying
    • Gene Therapy
    • Mitochondrial Targeting Sequence (MTS)
    • Optogenetics
    • Clinical development Summary
  • Investors
    • Company Overview
    • Financial press releases
    • Investor Newsletters
    • Events & presentations
    • Stock information & Financial agenda
    • Governance
    • Documentation
  • Media

Documentation

  • Home >
  • Investors & media >
  • Documentation
14 June 2023
Financial statements and reports, General Assembly, General meetings

Supplementary report of the Board of Director dated 23 March 2023 Open in new window

14 June 2023
Financial statements and reports, General Assembly, General meetings

Supplementary report of the Board of Director dated 22 December 2022 Open in new window

10 May 2023
Financial statements and reports

2022 Universal Registration Document Open in new window

28 July 2022
Financial statements and reports

2022 Half-Year Financial Report Open in new window

29 April 2022
Financial statements and reports

2021 Universal Registration Document Open in new window

29 July 2021
Financial statements and reports

2021 Half-Year Financial Report Open in new window

08 April 2021
Financial statements and reports, General meetings

Auditors’ report on 2020 Consolidated Financial Statements in accordance with IFRS Open in new window

08 April 2021
Financial statements and reports, General meetings

Auditors’ report on 2020 Financial Statements in accordance with French Gaaps Open in new window

08 April 2021
Financial statements and reports, General meetings

2020 Universal Registration Document Open in new window

22 October 2020
Financial statements and reports, Regulated information

Amendment to the 2019 Universal Registration Document Open in new window

  • View previous 9 articles
  • 1
  • 2
  • 3
  • View next 9 articles
© 2025 Gensight Biologics
  • Terms of use
  • Sitemap
  • Contact
  • Credits
  • Cookies management
Go back to the page of the page